Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

• By Sue Sutter

Related Content

Sarepta's Eteplirsen Review Delay Emboldens Duchenne Community

May 25 2016

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Sep 20 2016

Eteplirsen Review Timeline: CDER Director Was Involved Early And Often

Sep 20 2016

Sarepta, FDA And The Dangers Of Strong Early Results

May 02 2016

Duchenne Muscular Dystrophy: Second Product Isn't The Charm

Jan 15 2016

Related Companies

Sarepta Therapeutics, Inc.

Additional Topics

Drug Review Approvals Regulation Neurology BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window